Downregulation of α-galactosidase A upregulates CD77: Functional impact for Fabry nephropathy

Kidney International

Volumn 75, Issue 4, 2009, Pages 399-407

  Thomaidis, Thomas ^a   Relle, Manfred ^a   Golbas, Mitra ^a   Brochhausen, Christoph ^a   Galle, Peter R ^a   Beck, Michael ^a   Schwarting, Andreas ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b SANA KLINIKUM OFFENBACH   (Germany)

Author keywords

galactosidase; Anderson Fabry disease; CD77; Enzyme replacement therapy; Gb3; RNA interference

Indexed keywords

AGALSIDASE ALFA; ALPHA GALACTOSIDASE; GLOBOTRIAOSYLCERAMIDE; SHORT HAIRPIN RNA;

ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; CELL VIABILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME RECONSTITUTION; ENZYME REPLACEMENT; EPITHELIUM CELL; FABRY DISEASE; FEMALE; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; KIDNEY EPITHELIUM; MALE; MOLECULAR MODEL; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SCHOOL CHILD; UPREGULATION; URINE LEVEL;

ALPHA-GALACTOSIDASE; CELL LINE; EPITHELIAL CELLS; FABRY DISEASE; GENE EXPRESSION REGULATION; GENE SILENCING; GLOBOSIDES; HUMANS; RNA, SMALL INTERFERING; TRIHEXOSYLCERAMIDES;

EID: 59149106521     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.576     Document Type: Article

References (44)

1. Brady RO, Gal AE, Bradley RM et al. Enzymatic defect in Fabry's disease: ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-1167.
2. Shows TB, Brown JA, Haley LL et al. Assignment of alpha-galactosidase (alpha GAL) to the q22 leads to qter region of the X chromosome in man. Cytogenet Cell Genet 1978; 22: 541-544.
3. Hornbostel H, Scriba K. Excision of skin in diagnosis of Fabry's angiokeratoma with cardio-vasorenal syndrome as phosphatide storage disease. Klin Wochenschr 1953; 31: 68-69.
4. Vongemmingen G, Kierlan RR, Opitz JM. Angiokeratoma Corporis Diffusum (Fabry's disease). Arch Dermatol 1965; 91: 206-218.
5. Sweeley CC, Klionsky B. Fabry's disease: classification as a Shingolipidosis and partial characterization of a novel glycoplipid. J Biol Chem 1963; 238: 3148-3150.
6. Maloney MD, Lingwood CA. CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med 1994; 180: 191-201.
7. Sessa A, Meroni M, Battini G et al. Evolution of renal pathology in Fabry disease. Acta Paediatr Suppl 2003; 92: 6-8.
8. Ohshima T, Schiffmann R, Murray GJ et al. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice. Proc Natl Acad Sci USA 1999; 96: 6423-6427.
9. Elbashir SM, Harborth J, Lendeckel W et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 428-429.
10. Paddison PJ, Caudy AA, Bernstein E et al. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-958.
11. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 1443-1448.
12. He l, Hannon GJ. MicroRNAs. Small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
13. Henry EW, Rally CR. The renal lesion in angiokeratoma corporis diffusum (Fabry's disease). Can Med Assoc J 1963; 89: 206-213.
14. Rae AI, Lee JC, Hopper Jr J. Clinical and electron microscopy studies of a case of glycolipid lipoidosis (Fabry's disease). J Clin Pathol 1967; 20: 21-27.
15. Ashley GA, Shabbeer J, Yasuda M et al. Fabry disease: twenty novel alphagalactosidase A mutations causing the classical phenotype. J Hum Genet 2001; 46: 192-196.
16. LeDonne Jr NC, Fairley JL, Sweeley CC. Biosynthesis of alpha-galactosidase A in cultured Chang liver cells. Arch Biochem Biophys 1983; 224: 186-195.
17. Lee K, Jin X, Zhang K et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003; 13: 305-313.
18. Chen Y, Ming J, Goodrich L et al. Purification and characterization of Human alpha-galactosidase A expressed in insect cells using a Baculovirous vector. Protein Expr Purif 2000; 20: 228-236.
19. Wang AM, Desnick RJ. Structural organization and complete sequence of the human alpha-N-acetylgalactosaminidase gene: homology with the alpha galactosidase A gene provides evidence for evolution from a common ancestral gene. Genomics 1991; 10: 133-142.
20. Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002; 10: 549-561.
21. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA 2003; 100: 9779-9784.
22. Saxena S, Jonsson ZO, Dutta A. Small RNAs with imperfect match to endogenous mRNA repress translation. Implications for off-target activity of small inhibitory RNA in mammalian cells. J Biol Chem 2003; 278: 44312-44319.
23. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
24. Miyagishi M, Taira K. U6 promoter-driven siRNAs with four uridine 3 overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002; 20: 497-500.
25. Rubinson DA, Dillon CP, Kwiatkowski AV et al. Alentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406.
26. Barton GM, Medzhitov R. Retroviral delivery of small interfering RNA into primary cells. Proc Natl Acad Sci USA 2002; 99: 14943-14945.
27. Hommel JD, Sears RM, Georgescu D et al. Local gene knockdown in the brain using viral mediated RNA interference. Nat Med 2003; 9: 1539-1544.
28. Tiscornia G, Singer O, Ikawa M et al. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003; 100: 1844-1848.
29. Ohshima T, Murray GJ, Swaim WD et al. alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 1997; 94: 2540-2544.
30. Shen JS, Meng XL, Schiffmann R et al. Establishment and characterization of Fabry disease endothelial cells with an extended lifespan. Mol Genet Metab 2007; 92: 137-144.
31. Tétaud C, Falguières T, Carlier K et al. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77mAb and verotoxin-1. J Biol Chem 2003; 278: 45200-45208.
32. Menge C, Stamm I, Blessenohl M et al. Verotoxin 1 from Escherichia coli affects Gb3/CD77+ bovine lymphocytes independent of interleukin-2, tumor necrosis factor-alpha, and interferon-alpha. Exp Biol Med (Maywood) 2003; 228: 377-386.
33. Askari H, Kaneski CR, Semino-Mora C et al. Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 2007; 451: 823-834.
34. Detry G, Drénou B, Ferrant A et al. Tracking the follicular lymphoma cells in flow cytometry: characterisation of a new useful antibody combination. Eur J Haematol 2004; 73: 325-331.
35. Johannes L. The epithelial cell cytoskeleton and intracellular trafficking I. Shiga toxin B-subunit system: retrograde transport, intracellular vectorization, and more. Am J Physiol Gastrointest Liver Physiol 2002; 283: G1-G7.
36. Jackson T, Van Exel C, Reagans K et al. Comparison of adhesion mechanisms and surface protein expression in CD77-positive and CD77-negative Burkitt's lymphoma cells. Cell Mol Biol 2001; 47: 1195-1200.
37. Ioannou YA, Zeidner KM, Gordon RE et al. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001; 68: 14-25.
38. Young E, Mills K, Morris P et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005; 94: 51-54.
39. Taga S, Carlier K, Mishal Z et al. Intracellular signaling events in CD77-mediated apoptosis of Burkitt's lymphoma cells. Blood 1997; 90: 2757-2767.
40. Mangeney M, Lingwood CA, Taga S et al. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res 1993; 53: 5314-5319.
41. Mangeney M, Richard Y, Coulaud D et al. CD77: an antigen of germinal center B cells entering apoptosis. Eur J Immunol 1991; 21: 1131-1140.
42. Pastores GM, Thadhani R. Advances in the management of Anderson-Fabry disease: enzyme replacement therapy. Expert Opin Biol Ther 2002; 2: 325-333.
43. Aerts JM, Groener JE, Kuiper S et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 2008; 105: 2812-2817.
44. Relle M, Mayet WJ, Strand D et al. Proteinase 3/myeloblastin as a growth factor in human kidney cells. J Nephrol 2003; 16: 831-840.